Cargando…

The O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and clinical outcomes of Ewing sarcoma patients treated with irinotecan and temozolomide

BACKGROUND: There remains an unmet need to identify molecular biomarkers in Ewing sarcoma (ES). We sought to assess the influence of the O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation on response and progression-free survival (PFS) following initiation of irinotecan and temozol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salah, Samer, Naser, Walid, Jaber, Omar, Saleh, Yacob, Mustafa, Rawan, Abuhijlih, Ramiz, Abuhijla, Fawzi, Ismaeel, Taleb, Yaser, Sameer, Sultan, Iyad, Mustafa, Nour, Tbakhi, Abdelghani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Via Medica 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746634/ https://www.ncbi.nlm.nih.gov/pubmed/36523794 http://dx.doi.org/10.5603/RPOR.a2022.0084

Ejemplares similares

Radiation oncology practice during COVID-19 pandemic in developing countries
por: Abuhijla, Fawzi, et al.
Publicado: (2021)

PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O(6)-methylguanine DNA damage in glioblastoma
por: Wu, Shaofang, et al.
Publicado: (2021)

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
por: Cai, W, et al.
Publicado: (2010)

Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo
por: Chen, Thomas C., et al.
Publicado: (2018)

O6-Methylguanine-Methyltransferase (MGMT) Promoter Methylation Status in Glioma Stem-Like Cells is Correlated to Temozolomide Sensitivity Under Differentiation-Promoting Conditions
por: Villalva, Claire, et al.
Publicado: (2012)

Temozolomide Induces the Acquisition of Invasive Phenotype by O6-Methylguanine-DNA Methyltransferase (MGMT)(+) Glioblastoma Cells in a Snail-1/Cx43-Dependent Manner
por: Kochanowski, Paweł, et al.
Publicado: (2021)

O(6)‐Methylguanine‐DNA Methyltransferase (MGMT) as a Determinant of Resistance to Camptothecin Derivatives
por: Okamoto, Ryo, et al.
Publicado: (2002)

O(6)-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy
por: Yu, Wei, et al.
Publicado: (2020)

PARP1-MGMT complex underpins pathway crosstalk in O(6)-methylguanine repair
por: Cropper, Jodie D., et al.
Publicado: (2022)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

O(6)-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation
por: Kreth, Simone, et al.
Publicado: (2011)

Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA
por: Anderson, Peter, et al.
Publicado: (2023)

Primary radiation therapy for advanced‐stage laryngeal cancer: A laryngo‐esophageal dysfunction disease‐free survival
por: Mohamad, Issa, et al.
Publicado: (2022)

Pretreatment neutrophil‐to‐lymphocyte ratio as a potential prognostic biomarker for newly diagnosed patients with metastatic castration‐sensitive prostate cancer
por: Salah, Samer, et al.
Publicado: (2021)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Radiation Therapy for Prostate Cancer: Challenges Facing Low-Middle Income Countries During COVID Pandemic
por: Abu-Hijlih, Ramiz, et al.
Publicado: (2022)

O6-methylguanine-DNA methyltransferase (MGMT) Promoter methylation is a rare event in soft tissue sarcoma
por: Jakob, Jens, et al.
Publicado: (2012)

The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine
por: Cannella, Lucia, et al.
Publicado: (2023)

Bone marrow involvement in patients with metastatic castration sensitive prostate cancer
por: Shahait, Mohammed, et al.
Publicado: (2022)

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
por: Alnahhas, Iyad, et al.
Publicado: (2020)

Use Of Temozolomide In Parathyroid Carcinoma With Negative Mgmt Promoter Methylation
por: Reddy, Niyoti, et al.
Publicado: (2021)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic
por: Hashem, Hasan, et al.
Publicado: (2020)

The role of direct DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) in high grade malignant glioma
por: Manoj, M Jeru, et al.
Publicado: (2014)

Immunohistochemical Assessment of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and Its Relationship with p53 Expression in Endometrial Cancers
por: Lee, Kyung Eun
Publicado: (2013)

Determining methylation status of methylguanine DNA methyl transferase (MGMT) from formalin-fixed, paraffin embedded tumor tissue
por: de Abreu, Francine B., et al.
Publicado: (2014)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis
por: Alnahhas, Iyad, et al.
Publicado: (2021)

Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival
por: Robinson, C G, et al.
Publicado: (2010)

O(6)-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas
por: Fan, C-H, et al.
Publicado: (2013)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Frequent MGMT (0(6)-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience
por: Baur, Martina, et al.
Publicado: (2010)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study
por: Asaftei, Sebastian Dorin, et al.
Publicado: (2021)

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
por: Middleton, M. R., et al.
Publicado: (1998)

O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer
por: Hasina, Rifat, et al.
Publicado: (2013)

Enhancing value of quality assurance rounds in improving radiotherapy management: a retrospective analysis from King Hussein Cancer Center in Jordan
por: Khader, Jamal K., et al.
Publicado: (2019)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells
por: Ryu, Chung Heon, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8qpssdjqc78ip462rjhoa1cjnu